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ABSTRACT
Purpose: While there is an urgent need for diagnosis and therapeutic intervention in patients 
with primary immunodeficiency diseases (PIDs), current genetic tests have drawbacks. 
We retrospectively reviewed the usefulness of flow cytometry (FCM) as a quick tool for 
immunophenotyping and functional assays in patients suspected to have PIDs at a single 
tertiary care institute.
Methods: Between January 2001 and June 2018, patients suspected of having PIDs were subjected 
to FCM tests, including lymphocyte subset analysis, detection of surface- or intracellular-target 
proteins, and functional analysis of immune cells, at Samsung Medical Center, Seoul, Korea. The 
genetic diagnosis was performed using Sanger or diagnostic exome sequencing.
Results: Of 60 patients diagnosed with definite or probable PID according to the European 
Society of Immune Deficiencies criteria, 24 patients were provided with useful information 
about immunological dysfunction after initial FCM testing. In 10 patients, the PID diagnosis 
was based on abnormal findings in FCM testing without genetic tests. The FCM findings 
provided strong evidence for the diagnosis of severe combined immunodeficiency (n = 6), 
X-linked chronic granulomatous diseases (CGD) (n = 6), leukocyte adhesion deficiency type 1 
(n = 3), X-linked agammaglobulinemia (n = 11), autoimmune lymphoproliferative syndrome-
FASLG (n = 1), and familial hemophagocytic lymphohistiocytosis type 2 (n = 1), and probable 
evidence for autosomal recessive-CGD (n = 2), autosomal dominant-hyper-immunoglobulin 
E (IgE)-syndrome (n = 1), and STAT1 gain-of-function mutation (n = 1). In PIDs derived from 
PIK3CD (n = 2), LRBA (n = 2), and CTLA4 mutations (n = 3), the FCM test provided useful 
evidence of immune abnormalities and a tool for treatment monitoring.
Conclusions: The initial application of FCM, particularly with known protein targets on 
immune cells, would facilitate the timely diagnosis of PIDs and thus would support clinical 
decisions and improve the clinical outcome.
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INTRODUCTION
Primary immunodeficiency diseases (PIDs) are a heterogeneous group of inherited disorders 
of the immune system. More than 300 genetic defects have been detected as causes of PIDs.1 
The estimated prevalence of PIDs has been reported to be 2.3 per 100,000 persons in Japan,2 
while that in Korea is 1.125 per 100,000 children based on questionnaire surveys in 2012.3 
However, recent reports suggest that PIDs are more common than previously believed, 
and the prevalence of any diagnosis in the US increased from 38.9 to 50.5 and 29.1 to 41.1 
per 100,000 among publicly and privately insured persons, respectively, between 2001 and 
2007.4 In addition, during the 10 years from 2004, which the European Society of Immune 
Deficiencies (ESID) online registry system has been operational, the number of patients 
registered has grown substantially; after 4 years, more than 7,000 patients were registered 
and, as of 25 June 2014, 19,355 patients in Europe have been registered as having a PID.5
PIDs have been diagnosed using the ESID registry (2014) criteria6 based on clinical 
manifestations and hematological/biochemical laboratory tests. The clinical phenotypes 
of patients are heterogeneous; therefore, the accurate identification of an underlying PID 
may not always be possible. The appropriate diagnosis of PIDs is crucial for initiating proper 
management and reducing infection-associated morbidity and mortality, and therefore, 
detection of specific protein abnormalities or significant genetic variants is crucial. 
Particularly, molecular tests are essential for identifying the structural abnormalities of 
genes, thus enabling accurate diagnosis.7,8 However, genetic tests are time-consuming, 
laborious and costly. Moreover, targeted single gene tests may miss causative mutations. 
Exome sequencing has recently been received attention as a diagnostic tool for many rare 
genetic diseases, including PIDs. However, it has been reported that exome sequencing 
detected causative genetic defects in about 40% of patients with PIDs with variable size of 
panels.9,10 Exome sequencing is still limited as a diagnostic test because of the high cost, 
labor intensity and turn-around time. Flow cytometry (FCM) is a diagnostic tool used for 
both immunophenotyping and functional assays of immune cells in real time. FCM has been 
used to assess functional characteristics linked to PIDs.11 Thus, it can be an initial screening 
test for rapid diagnosis in a spectrum of patients suspected of having PIDs. For example, the 
absence of T cells, natural killer (NK) cells or both in severe combined immunodeficiency 
(SCID), absence of B cells in agammaglobulinemia, or markedly reduced dihydrorhodamine 
(DHR) in X-linked chronic granulomatous diseases (XL-CGD) provide very significant 
evidences of PIDs and should draw the immediate attention of clinicians to start therapeutic 
intervention while awaiting results of confirmatory genetic tests.
In this study, we retrospectively reviewed the use of FCM tests for the diagnosis of PIDs at 
a single tertiary care center in Korea. The aims of this study were as follows: 1) to highlight 
the experiences of a diagnostic approach for patients with PIDs using FCM, and 2) to suggest 
FCM tests, based on positive findings as a first line diagnostic approach and treatment 
monitoring tool in certain PID groups.
MATERIALS AND METHODS
Patients
Between January 2001 and June 2018, 115 patients who were highly suspected of having PIDs 
were subjected to FCM or genetic tests or both at the Samsung Medical Center, Seoul, Korea. 
293https://e-aair.org https://doi.org/10.4168/aair.2020.12.2.292
Primary Immunodeficiency Diagnosis by Flow Cytometry
After exclusion of 27 patients with secondary hemophagocytic lymphocytic histiocytosis, 8 
carriers, and 20 patients who did not meet the ESID criteria (2014), 60 patients were included 
in this study (Fig. 1). Clinical manifestations and laboratory findings were collected from 
electric medical records. The study was approved by the Institutional Review Board (IRB) of 
the Samsung Medical Center (IRB No. 2019-07-175-003) and performed in accordance with 
the principles of the Declaration of Helsinki.
Multicolor flow cytometry
Whole blood samples were collected from patients. The cells were incubated with the surface 
marker antibodies for 30 minutes at 4°C and washed twice with phosphate-buffered saline 
(PBS). Red blood cells were lysed using fluorescent activated cell-sorting (FACS) Lysing 
Solution (Becton Dickinson, San Jose, CA, USA). For intracellular staining, the cells were 
incubated with a fixation and permeabilization mixture (eBioscience, San Diego, CA, USA) 
on ice for 1 hour. Then, the cells were washed with PBS and incubated with the antibodies 
at 24°C for 15 minutes. After the final wash, the cells were resuspended in PBS and FACS 
acquisition was performed. The neutrophils were activated with phorbol 12-myristate 
13-acetate (PMA; Sigma-Aldrich, St. Louis, MO, USA) for 15 minutes for the DHR assay, while 
the lymphocytes were similarly treated for the cluster of differentiation (CD) 11b/CD18 and 
CD40/CD40L tests. For phospho-flow analysis of the intracellular phosphorylated signal 
transducer and activator of transcription 1 (pSTAT1), peripheral blood mononuclear cells 
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35 were not eligible due to:
Secondary HLH (n = 27)
Carrier (n = 8)
60 were finally included and classified
following 2015 IUIS classification
20 did not meet the ESID criteria
      as definite or probable
80 were assessed for eligibility
γc deficiency (n = 4)
T-B+ SCID (n = 2)
115 patients suspected PID
WAS (n = 6)
AD-HIES (n = 1)
HIES (n = 2)
BTK deficiency (n = 11)
Undetermined CVID (n = 3)
Activated PI3K-δ (n = 2)
Absence of B cells (n = 2)
IgA deficiency (n = 1)
CTLA4 deficiency (n = 3)
LRBA (n = 2)
ALPS-FASLG (n = 1)
IPEX like SD (n = 1)
XIAP (n = 1)
FHL (n = 1)
XL CGD (n = 6)
CGD (n = 5)
LAD (n = 3)
AR CGD (n = 2)
STAT1 GOF mutation (n = 1)
Cellular and humoral
immunity (n = 6)
Combined immuno-





Defects in intrinsic and
innate immunity (n = 17)
Fig. 1. Enrollment and classification of patients. 
PID, primary immunodeficiency disease; HLH, hemophagocytic lymphohistiocytosis; ESID, European Society of Immune Deficiencies; IUIS, International Union 
of Immunological Societies; WAS, Wiskott-Aldrich syndrome; AD-HIES, autosomal dominant-hyper-IgE syndrome; HIES, hyper-IgE syndrome; BTK, Bruton's 
tyrosine kinase; CVID, common variable immune deficiency; IgA, immunoglobulin A; CTLA4, cytotoxic T-lymphocyte associated protein 4; ALPS, autoimmune 
lymphoproliferative syndrome; AR-CGD, autosomal recessive chronic granulomatous diseases; FHL, familial hemophagocytic lymphohistiocytosis; LAD, 
leukocyte adhesion deficiency; SCID, severe combined immunodeficiency; IPEX-like SD, immunodysregulation polyendocrinopathy enteropathy X-linked 
syndrome; XL-CGD, X-linked-chronic granulomatous diseases; STAT1, signal transducer and activator of transcription 1; GOF, gain-of-function.
were acquired by density gradient centrifugation using Ficoll (General Electric Healthcare 
Bio-Sciences, Uppsala, Sweden) and stimulated with interferon (IFN)-γ. For the DHR and 
pSTAT1 assays, the stimulation index was calculated for gated neutrophils and lymphocytes by 
dividing the median fluorescent intensity (MFI) of stimulated cells with the MFI of unstimulated 
cells. The flow cytometer and analysis software used were FACSCanto II (Becton Dickinson) 
and FACSDiva ver. 8.0 (Becton Dickinson), respectively. Immunophenotyping was performed 
using the panels of antibodies depending on the suspected PIDs. The unstained cells and cells 
stained with the relevant isotype antibodies were used as controls. Detailed information about 
the antibodies and clones is provided in Table 1.
Sanger and exome sequencing
Genomic DNA was extracted from peripheral blood leukocytes using the Wizard Genomic 
DNA purification kit (Promega, Madison, WI, USA) according to the manufacturer's 
instructions and each gene mutation analysis was performed on the archival samples. 
The primers were designed in-house. Direct sequencing was performed using the ABI 
Prism 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) with the BigDye 
Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems). The results were 
analyzed using the Sequencing Analysis software ver. 5.2 (Applied Biosystems). Exome 
sequencing was performed using the Illumina TruSight panel with the MiSeq HiSeq 2500 
platform (Illumina, San Diego, CA, USA). The data were analyzed using the pipeline software 
programs, which were optimized in the Green Cross Genome Laboratory.
Data analysis
We categorized the utility of FCM tests for clinical diagnosis of PIDs. Depending on the 
comparability between FCM and genetic diagnosis, it was categorized as providing strong 
evidence, probable evidence or helpful clues (Fig. 2). Furthermore, where the FCM test was 
useful for monitoring the treatment response of PIDs is also reported. When FCM could 
provide evidence to diagnose specific PIDs, we categorized as strong. Probable evidence 
provided altered findings by FCM for highly suspecting PIDs but rather for broader categories 
of PIDs, so the molecular test was required. The helpful clue category included PIDs where 
the FCM findings suggested immunological abnormalities but were not specific for diagnosis 
and providing clues of treatment responses.
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Table 1. Flow cytometry panels for primary immunodeficiency disease diagnosis
Panels Target proteins (clone) Manufacturers
BTK panel BTK (53), CD14 (M0P9) Becton Dickinson
Double negative T-cell panel, ALPS CD3 (SK7), CD4 (SK3), CD8 (SK1), TCR-ab (WT31), TCR-gd (011F2) Becton Dickinson
Extended B cell panel CD10 (ALB1), CD19 (SJ25C1), CD24 (SN3), CD38 (T16), CD27 (0323), 
IgD (IA6-2)
Beckman coulter, eBioscience,  
Becton Dickinson
Extended T cell panel CD45RA (HI100), CD45RO (UCHL1), CCR7 (150503) eBioscience, Becton Dickinson
Hyper-IgM panel CD40 (5C3), CD40L (TRAP1) Becton Dickinson
Leukocyte adhesion deficiency panel CD11b (ICRF44), CD18 (6.7) Becton Dickinson
Lymphocyte subset CD3 (SK7), CD19 (SJ25C1), CD56 (NCAM16.2), CD4 (SK3), CD8 (SK1) Becton Dickinson
Neutrophil respiratory burst test (DHR) NADPH oxidase Sigma-Aldrich
Perforin, HLH panel CD8 (SK1), CD56 (NCAM16.2), Perforin (8G9) Becton Dickinson
Regulatory T cell panel FOXP3 (PCH101), CD25 (2A3), CD4 (RPA-T4) eBioscience, Becton Dickinson
STAT1 phosphorylation panel CD3 (SK7), pSTAT1 (pY701) Becton Dickinson
BTK, Bruton's tyrosine kinase; ALPS, autoimmune lymphoproliferative syndrome; DHR, dihydrorhodamine; HLH, hemophagocytic lymphohistiocytosis; CD, 
cluster of differentiation; TCR, T-cell receptor; STAT1, signal transducer and activator of transcription 1; pSTAT1, phosphorylated signal transducer and activator 
of transcription 1; NADPH, nicotinamide adenine dinucleotide phosphate; CCR7, C-C chemokine receptor type 7; IgD, immunoglobulin D.
RESULTS
Strong evidence: SCID, X-linked agammaglobulinemia (XLA), XL-CGD, leukocyte 
adhesion deficiency (LAD), autoimmune lymphoproliferative syndrome (ALPS)-
FASLG and familial hemophagocytic lymphohistiocytosis (FHL)
Six patients had experienced frequent pneumonia, lung abscess, or orbital cellulitis at 3–7 
months of age. Their lymphocyte subset results showed that the T cells were markedly 
decreased to 0%–4% (Supplementary Fig. S1), which suggested that these patients had 
issues with T cell generation and differentiation (Table 2). All the patients were presumptively 
diagnosed with SCID. Among them, 4 were confirmed to have γ chain (γc) deficiency due 
to the IL2RG gene mutation, whereas the others did not proceed to take genetic tests but 
they could have started the treatment based on the FCM results. Of the 11 patients finally 
diagnosed with Bruton's XLA due to the BTK mutation (Table 3), all 5 who were subjected to 
lymphocyte subset analysis had almost no circulating CD19+ B cells. Two of the five patients 
tested for intracellular Bruton's tyrosine kinase (BTK) protein expression on monocytes 
showed markedly reduced expression (Supplementary Fig. S2), whereas the other 3 having 
TTTG deletion in intron 15 showed moderately reduced expression. Four XLA patients 
referred from other hospitals for therapeutic options, including intravenous immunoglobulin 
(IVIG) and hematopoietic stem cell transplantation (HSCT), were not subjected to FCM and 
were diagnosed only using genetic tests.
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Categorization of PIDs
based on usefulness of FCM
Strong evidence by FCM
Absence or abnormal increase of specific subset
Altered expression of functional proteins
Probable evidence by FCM
Mild to moderate alteration of functional proteins
Helpful clue & treatment monitoring by FCM
Mild to moderate alteration of subset
SCID, XLA, XL-CGD, LAD,
ALPS-FASLG, FHL, WAS*,†
AR-CGD, AD-HIES, STAT1,
WAS*,†, IPEX like SD*, XIAP*
PIK3CD, CTLA4,
undetermined CVID, LRBA*
Fig. 2. Categorization of PIDs based on the usefulness of Flow cytometry for diagnosis. 
PID, primary immunodeficiency disease; FCM, flow cytometry; AD-HIES, autosomal dominant-hyper-IgE syndrome; ALPS, autoimmune lymphoproliferative 
syndrome; AR-CGD, autosomal recessive-chronic granulomatous diseases; CTLA4, cytotoxic T-lymphocyte associated protein 4; CVID, common variable immune 
deficiency; FHL, familial hemophagocytic lymphohistiocytosis; IPEX-like SD, Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome; LAD, 
leukocyte adhesion deficiency; SCID, Severe combined immunodeficiency; WAS, Wiskott-Aldrich syndrome; XIAP, X-linked inhibitor of apoptosis protein; XLA, 
X-linked agammaglobulinemia; XL-CGD, X-linked-chronic granulomatous diseases. 
*FCM was not performed for these diseases in this study; †We suggest that WAS could be divided into 2 categories based on the variants that influence protein 
expression.
Table 2. FCM and genetic test findings of severe combined immunodeficiency patients (n = 6)
Patient Sex Age* 
(mon)
FCM Genetic test
CD3+ T cells CD19+ B cells CD16/56+ NK cells Gene Mutation Amino acid Inheritance
Count (/µL) % Count (/µL) % Count (/µL) %
1 M 4 4 0.21 1,745 97.2 31 1.72 IL2RG c.548T > C p.Leu183Ser XLR
2 M 7 58 3.2 1,311 92.3 64 4.5 IL2RG c.854 + 1dupG p.? XLR
3 M 3 3 0.2 1,450 99.1 4 0.4 IL2RG c.854G > A p.Arg285Gln XLR
4 M 3 < 10 0.0 200 95.0 < 10 2.0 IL2RG c.854G > A p.Arg285Gln XLR
5 M 7 20 1.0 1,950 80.0 0 0.0 NT NT NT NT
6 M 3 0 0.0 614 54.3 519 45.9 NT NT NT NT
FCM, flow cytometry; M, male; NT, not tested; CD, cluster of differentiation; NK, natural killer; XLR, X-linked recessive. *Age when intravenous immunoglobulin started.
Four of the 11 patients with XL-CGD had deep seated infections, including liver abscesses 
(Serratia marcescens, n = 1), splenic abscesses (Candida species, n = 1), osteomyelitis (n = 1) 
and cellulitis (Burkholderia cepacia, n = 1), which implied susceptibility to bacterial infections 
(Table 4). Four patients presenting with post-Bacille Calmette-Guérin lymphadenitis 
(n = 2), tuberculosis lymphadenitis (n = 1), and pneumonia with pleural effusion and 
hepatosplenomegaly (n = 1).12 Three patients had no clinical records at our center. The 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase function measured by the 
DHR tests in these 11 male patients showed profound abnormalities, such as having almost 
no respiratory burst activities (Supplementary Fig. S3). These findings strongly suggested 
a diagnosis of XL-CGD. Subsequently, a CYBB gene mutation was detected in all 6 patients 
subjected to genetic tests.
The 3 patients who manifested omphalitis, otitis media or mastoiditis were subjected 
to CD18/CD11b LAD panel tests (Table 4). The results of the FCM showed the absence 
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Table 3. Flow cytometry and genetic test findings of X-linked agammaglobulinemia patients (n = 11)
Patient Sex Age*  
(yr)
FCM Genetic test
CD19+ B cells Intracellular BTK expression Gene Mutation Amino acid Inheritance
Count (/µL) % Patient (%) Control (%)
1 M 43 3 0.1 15.7 85.0 BTK c.863G > A p.Arg288Trp XLR
2 M 3 0 0.0 60.2 93.9 BTK c.1567-12_1567-9delTTTG p.? XLR
3 M 41 0 0.0 45.6 97.0 BTK c.1567-12_1567-9delTTTG p.? XLR
4 M 3 0 0.0 88.6 94.0 BTK c.1581_1584delTTTG p.Cys527Trpfs*2 XLR
5 M 11 0 0.0 NT NT BTK c.1064T > A p.Ile355Asn XLR
6 M 38 NT NT 2.8 92.4 BTK c.939C > T r.939_975del; 
p.Lys314ThrfsX5
XLR
7 M 9 NT NT NT NT BTK c.1205T > C p.Leu402Pro XLR
8 M 17 NT NT NT NT BTK c.1567-12_1567-9delTTTG p.? XLR
9 M 13 NT NT NT NT BTK Outside† Not known XLR
10 M 23 NT NT NT NT BTK c.82delC p.Arg28Alafs*5 XLR
11 M 1 NT NT NT NT BTK c.82delC p.Arg28Alafs*5 XLR
FCM, flow cytometry; CD, cluster of differentiation; BTK, Bruton tyrosine kinase; Control, healthy control; M, male; NT, not tested; XLR, X-linked recessive.
*Age intravenous immunoglobulin was started. †Outside means that the genetic tests had been performed in referred hospital and the detailed information of 
genetic tests were not provided.
Table 4. Flow cytometry and genetic test findings of X-linked chronic granulomatous diseases patients (n = 11) and leukocyte adhesion deficiency patients (n = 3)




(MFI ratio* or %†)
Control  
(MFI ratio or %)
Gene Mutation Amino acid Inheritance
1 M 4 mon DHR 1.3 130.2 CYBB c.1078_1080delinsAA p.Asp360Asnfs*26 XLR
2 M 3 yr DHR 1.5 101.0 CYBB c.1133A > G p.Asp378Gly XLR
3 M 7 yr DHR 1.11 35.7 CYBB c.176G > A Ala55Asp XLR
4 M 5 yr DHR 1.3 98.1 CYBB c.897 + 2T > C Exon 8skipping XLR
5 M 19 yr DHR 1.1 156.9 CYBB Outside‡ Not known XLR
6 M 20 yr DHR 1.3 72.6 CYBB Outside‡ Not known XLR
7 M 6 yr DHR 1.53 18.8 NT NT NT NT
8 M 13 yr DHR 0.6 99.9 NT NT NT NT
9 M 5 yr DHR 0.9 49.0 NT NT NT NT
10 M 6 yr DHR 1.1 391.6 NT NT NT NT
11 M 23 yr DHR 1.4 420.0 NT NT NT NT
12 F 2 yr CD18/CD11 0.0 99.9 ITGB2 c.533C > T p.Pro178Leu AR
13 F 6 yr CD18/CD11 0.0 100.0 ITGB2 c.533C > T p.Pro178Leu AR
c.82_95del14 p.Phe28Leufs*26
14 F 2 mon CD18/CD11 0.0 99.5 NT NT NT NT
FCM, flow cytometry; AR, autosomal recessive; Control, healthy control; DHR, dihydrorhodamine; CD, cluster of differentiation; F, female; M, male; NT, not 
tested; XLR, X-linked recessive; MFI, median fluorescence intensity.
*MFI ratio: median MFI of stimulated DHR test/median MFI of unstimulated DHR test; †The result of CD18/CD11 is presented as a percentage (%); ‡Outside means 
that the genetic tests had been performed in referred hospital and the detailed information of genetic tests were not provided.
of cell surface CD18 expression without and with stimulation, which strongly suggested 
a presumptive diagnosis of LAD1 (Supplementary Fig. S4). Two patients who had been 
subjected to genetic tests had mutations in the ITGB2 gene.
We had a 5-year-old patient who had experienced recurrent pneumonia, intestinal 
lymphangiectasia, and bacterial peritonitis induced by Escherichia coli. The lymphocyte subset 
analysis showed increased CD4+ T cells, but the ratio of CD4+/CD8+ T cells was within the 
reference range. However, the CD4 and CD8 double negative T-cell receptor (TCR)-αβ+ 
T cells (DNTs) were significantly increased to 6.9%. The presumptive diagnosis of ALPS 
was confirmed by a genetic test showing the heterozygous mutation of the FASLG gene 
[FASLG:c.436G>T, p.(Val146Leu)].
A 29-day-old female infant, the second baby born in full term (38 + 4 weeks, 3,500 g), was 
admitted because of mild fever and rapid breath. Her sister had died from sepsis, acute 
hepatitis, gastrointestinal bleeding, and pulmonary hemorrhage at 28 days of age. The result 
of her laboratory tests met the hemophagocytic lympho histiocytosis criteria 2004. The 
FCM test for intracytoplasmic perforin expression showed the complete absence of perforin 
expression in her NK cells and CD8+ T cells. However, her parent was healthy and had a 
comparable expression of perforin (data not shown). Subsequently, deleterious biallelic 
mutations of the PRF1 gene inherited from each parent were detected [PRF1:c.65delC, p. 
(Pro22Argfs*2), and c.1090_1091delCT, p.(Leu364Glufs*93)], which confirmed FHL2.
Probable evidence: autosomal recessive-chronic granulomatous disease 
(AR-CGD), autosomal dominant-hyper-IgE syndrome (AD-HIES) and signal 
transducer and activator of transcription 1 (STAT1) gain of function (GOF) 
mutation
Compared to XL-CGD, the respiratory burst activities of 2 AR-CGD patients identified having 
NCF1 and CYBA mutations were moderately reduced compared to healthy controls (Table 5). 
Both patients had histories of recurrent infections, including a lung abscess by Aspergillus 
fumigates and multiple fungal abscesses on the retroperitoneum and liver by Candida krusei.
A patient was diagnosed with AD-HIES induced by the loss of function (LOF) mutation of 
STAT3. This patient had presented with bronchiectasis, nontuberculous mycobacteria (NTM) 
pulmonary infection, and recurrent skin infections. The intracellular staining of interleukin 
(IL)-17 in PMA/ionomycin-activated CD4+ T-cells showed an almost absence of IL-17-secreting 
CD4+ T-cells (0.01% in patients vs. 2.36% in controls), which suggested abnormalities of the 
STAT3 signaling pathway.
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Table 5. Flow cytometry and genetic test findings of AR-chronic granulomatous disease patients (n = 2), autosomal dominant hyper-IgE syndrome (n = 1) and 
STAT1 mutation (n = 1)






(MFI ratio* or %†)
Control  
(MFI ratio or %)
Gene Mutation Amino acid Inheritance
1 F 1 DHR 68* 126 NCF1 Outside‡ Not known AR
2 M 10 DHR 88* 310 CYBA c.385G > A p.Glu129Lys AR
3 F 6 IL-17 0.01† 2.36 STAT3 c.1144C > T p.Arg382Trp AD
4 F 24 pSTAT1 3.4† 1.4 STAT1 c.800C > T p.Ala267Val AD
FCM, flow cytometry; AD, autosomal dominant; AR, autosomal recessive; Control, healthy control; DHR, dihydrorhodamine; IL, interleukin; pSTAT1, 
phosphorylated signal transducer and activator of transcription 1; F, female; M, male; MFI, median fluorescence intensity.
*MFI ratio: median MFI of stimulated DHR test/median MFI of unstimulated DHR test; †The result of pSTAT1 and IL17 were presented in percent (%); ‡Outside 
means that the genetic tests had been performed in referred hospital and the detailed information of genetic tests were not provided.
The 24-year-old female patient who had NTM and a recurrent superficial fungal infection had 
been referred13 for PID evaluation. In exome sequencing, a GOF mutation of STAT1 (c.800C 
> T) was detected. There was no abnormal finding in initial lymphocyte subset analysis, but 
the FCM analysis of intracellular pSTAT1 without and with stimulation by IFN gamma showed 
significantly increased expression of pSTAT1 without inhibition by the Janus kinase (JAK) 
inhibitor, ruxolitinib (Novartis Pharmaceutical Corporation, East Hanover, NJ, USA).
Helpful clues and utility for treatment monitoring: PIK3CD and CTLA4 
mutations and undetermined common variable immune deficiency (CVID)
The patients belonging to this category had abnormal lymphocyte subset results, including 
a slight to marked decrease in CD19+ B cells, decreased NK cells, or decreased regulatory 
T cells (Tregs) (Table 6). Female siblings, 24 and 20 years old, had been identified, using 
exome sequencing, as having an autosomal dominant CTLA4 mutation, after the initial 
diagnosis of CVID based on clinical findings and decreased B cells 10 years prior. The older 
sister had exhibited clinical manifestations such as thrombocytopenia, recurrent parotitis, 
hepatosplenomegaly and ulcerative colitis (chronic diarrhea and hematochezia) from birth 
and the younger sister was found to have hypogammaglobulinemia (immunoglobulin [Ig] G, 
347 mg/dL; reference 700-1,600 mg/dL) at 13 years of age. IVIG medication was commenced 
following the diagnosis of CVID. Even after IVIG treatment, both siblings experienced 
multiple episodes of illness, including anemia, thrombocytopenia, viral infection, and 
malignancies such as gastric cancer and myelodysplastic syndrome. Both patients had 
markedly decreased B-cells, and the older sister had a decreased CD4+FOXP3+ Tregs (1.8% 
CD4+ T cells in the patient as compared to 4.9% in the control) (Supplementary Fig. S5). 
Their mother has the same mutation but did not have clinical symptoms and had normal B- 
and T-cell proportions.
Two patients presenting lymphadenopathy and recurrent infections, such as acute otitis 
media and pneumonia, were diagnosed with a PIK3CD GOF mutation by exome sequencing. 
One patient was found to have a cervical lymph node abscess and lymphocyte infiltration in 
the colon. In these patients, the usual lymphocyte subset analysis did not show abnormal 
findings, but a more detailed analysis of naïve and memory T-cell subsets showed altered 
differentiation status of CD4+ and CD8+ T cells. Their initial analyses showed increased naïve 
B cells (CD19+IgD+ CD27− cells) and memory cytotoxic T cells (CD3+ CD8+ CD45RA cells) 
compared to age-matched values (Supplementary Fig. S6).14 After treatment with sirolimus, a 
mammalian target of rapamycin (mTOR) inhibitor, the altered status of T and B lymphocyte 
differentiation was improved in these patients with activated PIK3CD mutations.
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Table 6. Flow cytometry and genetic test findings of CTLA4 mutation patients (n = 3), PIK3CD mutation patients (n = 2) and undetermined common variable 
immune deficiency patients (n = 3)
Patient Sex Age  
(yr)
FCM Genetic test
CD3+ T cells CD19+ B cells CD16/56+ NK cells FOXP3+ CD4+ cells Gene Mutation Amino acid Inheritance
Count (/µL) % Count (/µL) % Count (/µL) % Count (/µL) %
1 F 24 2,020 81 110 4 200 8 10.61 1.8 CTLA4 c.406C > T p.Pro136Ser AD
2 F 13 840 87 30 3 100 10 NT NT CTLA4 c.406C > T p.Pro136Ser AD
3 F 58 1,203 59 243 12 552 27 NT NT CTLA4 c.406C > T p.Pro136Ser AD
4 F 10 549 70 110 14 110 14 NT NT PIK3CD c.3061G > A p.Glu1021Lys AD
5 M 2 2,320 68 341 10 682 20 NT NT PIK3CD c.3061G > A p.Glu1021Lys AD
6 F 32 1,942 88 0 0 88 4 NT NT NT NT NT Unknown
7 M 3 3,239 91 71 2 178 5 NT NT NT NT NT Unknown
8 F 5 2,501 66 344 9 764 20 NT NT NT NT NT Unknown
FCM, flow cytometry; CD, cluster of differentiation; NK, natural killer; AD, autosomal dominant; F, female; M, male; NT, not test.
Three patients were diagnosed with CVID based on clinical manifestations of recurrent 
infections, including pneumococcal pneumonia, pseudomonas sepsis, and lymphadenitis. 
Their lymphocyte subset analysis showed variably decreased B cell counts (0%–9%). 
Although genetic diagnosis by extensive molecular tests such as exome sequencing had 
not been performed yet, all the patients were under the IVIG therapy based on the ESID 
diagnostic criteria and the lymphocyte subsets were monitored.
DISCUSSION
We described the usefulness of FCM tests in diagnosing or deciding to start treatment in 
PIDs or both based on the experience at a single tertiary care hospital. In recent years, FCM 
has emerged as an extremely useful laboratory tool for evaluating patients with potential 
PIDs.15 Based on the 2017 International Union of Immunological Societies, genetic tests 
should be performed to confirm the diagnosis. However, in some cases such as XL-CGD and 
BTK that have a specific functional assay and a specific protein that can be detected, the FCM 
methodology could be an efficient laboratory tool to establish a specific diagnosis as well 
as monitor treatment responses. Moreover, performing lymphocyte subset analysis, which 
includes analyzing T, B, NK cells, and helper and cytotoxic T cells, provides the initial clue for 
insufficient immune system.
SCID is a group of diseases caused by genetic defects producing blockade or impairment 
of differentiation T-lymphocytes and, to a varying degree, other lymphocytes or cells of the 
myeloid lineage.16 In addition to the clinical phenotypes of SCID, distribution and absolute 
count of T, B, and NK cell subsets can provide clues regarding the extent to which the 
immune system is affected.17 The most common form affecting approximately 30%–60% of 
the patients is X-linked SCID caused by mutations in the gene encoding the common γc of 
the IL-2R18,19 which is mostly presented as T-B+ NK− SCID. Similarly, in our study the IL2RG 
mutation was found in 3 patients, who were subjected to genetic tests and were almost 
devoid of CD3+ T-cells (0%–3.2%) and NK cells (0%–4.5%). One patient who had T-B+ NK+ 
SCID (patient 6 in Table 2) may have a genetic defect such as in IL-7Rα, CD3δ, CD3ε, or CD3ζ 
although IL2RG and JAK3 mutations have also been shown to cause this phenotype.20 Now, 
allogeneic HSCT is the only curative option for SCID.21
XLA is characterized by decreased serum immunoglobulins of all isotypes and an almost 
complete absence of B-cells due to an arrest in B lymphocyte development. Intracellular 
BTK protein expression in XLA was shown to be reduced or absent.22,23 All 5 XLA patients 
who were subjected to the lymphocyte subset analysis showed an almost complete absence 
of CD19+ B cells (0.0%–0.1%); however, their BTK protein expression was variable. Two 
patients had significantly low (15.7% and 2.8%) levels but the other 3 patients who had 4 
nucleotide deletions in intron 15 of the BTK gene (BTK:c.1567-12_1567-9delTTTG) in common 
showed slight to moderate decrease (45.6%–88.6%) in BTK protein expression, and, in them, 
the expression of the BTK protein seemed to be affected to a lesser extent.
A DHR test measuring the neutrophil respiratory burst activities by NADPH oxidase function 
is a relatively quick and robust assay to diagnose and determine the potential genotype 
of CGD.24 In our patients, XL-CGD caused by a CYBB mutation had almost no neutrophil 
oxidative burst; however, AR-CGD by NCF1 had a partial defect, which was similar with the 
result of a previous report.22,25
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Likewise, PIDs caused by the LOF genetic mutation of the ITGB2 gene in LAD-1, the PRF 
gene in FLH2, and the STAT3 gene in AD-HIES showed absence or a marked decrease of the 
corresponding proteins or related functional proteins. For example, not only the expression 
of the STAT3 protein but also the development of the Th17 lineage through the JAK-STAT3 
signaling pathway was impaired in AD-HIES.26 Similarly, altered expression of CD132 (IL-2R) 
or CD127 (IL-7Rα) expression on lymphocytes in SCID, intracellular Wiskott-Aldrich syndrome 
protein, cytotoxic T-lymphocyte associated protein 4 (CTLA4) in CTLA4 deficiency, and 
X-linked inhibitor of apoptosis protein in X-linked lymphoproliferative disease type 2 could 
provide useful information prior to or while waiting for genetic test results.22,27
Moreover, FCM could be used for detection of GOF mutations, such as in the STAT1 gene and 
PIK3CD gene in our cases. FCM tests showed the relative increase of specific proteins (STAT1 
and phosphorylated STAT1) or cells (effector memory cytotoxic T cells) compared to healthy 
individuals in these gene abnormalities, thus with clinical suspicion, they could have suggested 
the defects in the immune system.28,29 Currently, there is no established criteria or cut-off of FCM 
tests in PIDs although Luk ADW et al.17 has suggested lower than 134/μL based on the CD19+ 
B-cell counts as an evidence of B cell negative genotypes and elevation of DNT cells expressing 
αβTCR in peripheral blood has been included in the revised diagnostic criteria for ALPS. More 
than 1.5% DNT cells out of the total lymphocytes or 2.5% of CD3+ lymphocytes have been 
proposed as the diagnostic requirement of ALPS; however, it does not provide the diagnosis of 
specific diseases and elevated DNT can also be observed in other immunodeficient conditions 
such as CGD and SCID.30,31 Therefore, we suggest FCM as one of the screening steps for PIDs.
FCM is being used to monitor treatment. Restoration of a specific immune subset or 
functional molecules after HSCT can be evidence of successful engraftment.32 Recently, 
targeted immunotherapy is becoming applicable in some PIDs due to an understanding of the 
underlying immunopathogenesis. Rapamycin (sirolimus) and mTOR inhibitors for the GOF 
PIK3CD mutation, and Abatacept, a CTLA-4 agonist, for LOF CTLA-4 or LRBA mutations, were 
successfully used.33,34 FCM may not be helpful during the initial stage due to the unavailability 
of a specific protein target or non-specific subset pattern; however, it provides evidence for 
treatment response by normalization of T and B cell differentiation statuses. Thus, in the 
absence of other objective markers of treatment monitoring, FCM would be helpful.35
Although FCM has been used quite successfully in our center, it has some limitations as a tool 
for PID diagnosis. First, the genotype and immunophenotype comparability is not complete. 
The level of protein expression detected by FCM can be dependent on structural variations 
caused by genetic defects. Less profound structural variation may not affect the protein 
expression to the level detected by FCM. Second, patients with PIDs commonly demonstrate 
heterogenous phenotypes, which are not typical for certain genetic abnormalities; therefore, 
applying a targeted FCM panel selected based on the clinician's first impression may result in 
the disease being missed. Third, although FCM is less expensive than a genetic test, it could 
be a burden to apply extensive antibody panels. Fourth, the need of fresh specimens presents 
another limitation.
To facilitate the diagnosis of PIDs, in addition to an efficient and potent laboratory diagnosis, 
understanding the current epidemiology of PIDs would be paramount. The number of patients 
with PIDs in 2013 was estimated to be 6 million worldwide36 and is ever increasing because of 
the recent progress in laboratory diagnosis. However, the epidemiology of PIDs in Korea has 
not been well investigated and the frequency is not well known, and only one epidemiological 
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study in Korea used a multicenter questionnaire survey from 2001 to 2005.3 Several countries are 
currently maintaining their own national registries37,38 or participating in multinational networks, 
which facilitates diagnosis and treatment decisions or manage by enabling information on 
patients with PIDs to be shared. There is no national registry of PIDs in Korea yet and when 
considering the continuous development of genetic diagnostic tools, the previous report may not 
reflect the current situation in Korea. Therefore, establishing a proper registry of Korean PIDs, 
an optimized network, and referral system for diagnosis and treatment would be expedient in the 
near future not only for the timely diagnosis to prevent comorbidity and reduce mortality but also 
for the effective management of the diseases so as to maintain the quality of life.
As described above, many PIDs are complex, and proper diagnosis is critical for improving 
prognosis. Although FCM might not provide a specific diagnosis, the initial application of 
FCM, particularly in the spectrum of PIDs with known protein targets on immune cells, 
would facilitate the timely diagnosis of PIDs, thereby supporting clinical decisions and 
improving clinical outcome.
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SUPPLEMENTARY MATERIALS
Supplementary Fig. S1
Flow cytometry dot plot of patient with severe combined immunodeficiency demonstrating 
markedly decreased (A) CD3+CD19− T cells, (B) CD3+CD16/56− T cells and (C) both 
CD4+CD8− and CD4−CD8+ T cells.
Click here to view
Supplementary Fig. S2
BTK expression in monocytes for evaluation of X-linked agammaglobulinemia. (A) In 
control, BTK is fully expressed compared to isotype control, however, (B) there is no 
difference in BTK expression between isotype control and test (patient) which suggests 
markedly reduced intracellular BTK protein.
Click here to view
Supplementary Fig. S3
DHR flow cytometry assay histograms demonstrating the change in fluorescence in 
neutrophils following stimulation. (A) In control, DHR was dihydrolyzed after stimulation 
and converted to fluorescent rhodamine, thus showed the shift signal. However, (B) in 
X-linked chronic granulomatous diseases patient, in the absence of nicotinamide adenine 
dinucleotide phosphate oxidase function, non-fluorescent DHR could not converted to 
rhodamine, so the fluorescent signal was not observed.
Click here to view
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Supplementary Fig. S4
Flow cytometry histograms of LAD panel from control subject and a patient with LAD type1. 
(A) In control, CD11b and CD18 were expressed after stimulation. (B) Patient demonstrated 
almost absent CD11b and CD18 expression on neutrophils.
Click here to view
Supplementary Fig. S5
Flow cytometry dot plot of Treg (A) in control and (B) in cytotoxic T-lymphocyte associated protein 4 
deficient patient. Patient's CD4+ T cells show decreased CD25+FOXP3+ Tregs compared to control.
Click here to view
Supplementary Fig. S6
Flow cytometry analysis of memory B-cell and T-cell in patient with PIK3CD gain of function 
mutation. Compared to control (A), (B) patients showed abnormal differentiation pattern. 
Especially, CD19+immunoglobulin D-CD27+ memory B cells, and CD45RA−CD27+ memory 
CD4+ and CD8+ T cell fractions are markedly decreased.
Click here to view
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